CURA leverages Transversal’s proprietary next-generation electrochemical platform to develop rapid, high-sensitivity blood biosensors for point-of-care use. Designed to support medication-assisted treatment (MAT) and therapeutic drug monitoring, this solution enables timely, data-driven clinical decisions directly at the site of care.